Why Investors Have These Biotech Stocks on Their Radar? - Cerus, Juno Therapeutics, Chiasma, and Sage Therapeutics

Monday, June 27, 2016 Research News J E 4

NEW YORK, June 27, 2016 /PRNewswire/ --

The Healthcare arena was one of the better-performing sectors on Friday, once again proving to be generally less sensitive to market downturns. This morning, has noted four equities in the Biotech space for close examination: Cerus Corp. (NASDAQ: CERS), Juno Therapeutics Inc. (NASDAQ: JUNO), Chiasma Inc. (NASDAQ: CHMA), and Sage Therapeutics Inc. (NASDAQ: SAGE). Sign up today for your complimentary trade alerts at:  

To access full PDF Research Packages for free, please visit the links below.



(You may have to copy and paste the links into your browser)

CERS Research Package:

JUNO Research Package:

CHMA Research Package:

SAGE Research Package:


Concord, California headquartered Cerus Corp.'s stock finished last Friday's session 4.13% lower at $6.03. A total volume of 1.61 million shares was traded, which was above their three months average volume of 1.08 million shares. The Company's shares have gained 7.10% in the past month and 4.15% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 2.34% and 8.17%, respectively. Additionally, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System, have a Relative Strength Index (RSI) of 51.68.

On Friday, shares in Seattle, Washington headquartered Juno Therapeutics Inc. ended the session 7.44% lower at $40.45. The stock recorded a trading volume of 5.45 million shares, which was higher than its three months average volume of 1.04 million shares. The Company's shares have gained 0.42% in the last one month and 12.33% in the previous three months. The stock is trading 3.45% below its 50-day moving. Moreover, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells, have an RSI of 42.49.

Shares in Newton, Massachusetts headquartered late-stage biopharmaceutical Company, Chiasma Inc., gained 1.09%, closing the session at $2.77. The stock recorded a trading volume of 889,341 shares, which was higher than its three months average volume of 564,810 shares. The Company's shares are trading 18.06% below their 50-day moving average. Additionally, shares of Chiasma, which focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases, have an RSI of 42.62.

On Friday, shares in Cambridge, Massachusetts headquartered clinical-stage biopharmaceutical Company, Sage Therapeutics Inc. recorded a trading volume of 1.74 million shares, which was above their three months average volume of 507,760 shares. The stock ended the day 7.34% lower at $28.54. The Company's shares are trading below their 50-day moving average by 14.64%. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 40.78.


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
MIHI Management Discusses its Innovative Groundbre...
Optimising the Use of Single Arm Trials in Cancer ...